Exploring immune checkpoint inhibition in combination with anti-angiogenic therapy for patients with EGFR- or ALK-positive advanced non-small cell lung cancer

Transl Lung Cancer Res. 2022 Sep;11(9):1734-1738. doi: 10.21037/tlcr-22-492.

Authors

Andrea De Giglio^{1

2}, Alessandro Di Federico¹, Giulio Metro³

Affiliations

¹ Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy.
² Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
³ Medical Oncology, Santa Maria Della Misericordia Hospital, Azienda Ospedaliera di Perugia, Perugia, Italy.

No abstract available

Publication types

Editorial
Comment